CA 125 for the monitoring of ovarian carcinoma during primary therapy
CA 125 for the monitoring of ovarian carcinoma during primary therapy
复制标题
CA 125 用于在初级治疗期间监测卵巢癌
DOI：
10.1016/0020-7292(87)90076-2
复制
发表时间：
1987
影响因子：
3.8
通讯作者：
R. Bast
中科院分区：
文献类型：
--
作者：
Philip T. Lawn;G. Malkasian;C. Whitney;Jonathan C. Berek;R. Bast
31例卵巢癌患者在肿瘤细胞减灭术和完成皮下化疗之间的时间间隔内用CA 125抗原决定簇进行监测。从前瞻性系列监测中出现了不同的CA 125测定趋势。在完成细胞减灭化疗后临床和手术无疾病的患者中，CA 125测定在细胞减灭化疗的前三个月内总是降至35 U/mL以下的水平，并保持在低水平。部分细胞减灭术患者血清CA 125水平下降，只有当有进一步治疗的反应。CA 125水平的下降率与临床结局相关。所有13例治疗3个月后血清CA 125高于35 U/mL的患者在随后的化疗后均出现持续性肿瘤，而在CA 125降低至低于35 U/mL水平的患者中，没有手术可检测到的肿瘤。在治疗期间测量CA 125可能允许早期改变为替代和最佳形式的治疗管理。治疗后3个月的CA 125水平似乎是对治疗反应的关键预测因子。（妇产科69：223，1987）
Thirty-one patients with ovarian cancer were monitored with the CA 125 antigenic determinant in the interval between cytoreductive surgery and the completion of sub-sequent chemotherapy. Distinct CA 125 assay trends have emerged from prospective serial monitoring. Among patients who were clinically and surgically free of disease after the completion of cytoreductive chemotherapy, the CA 125 assay always fell to levels under 35 U/mL within the first three months of cytoreductive chemotherapy, and stayed at low levels. Patients with partial cytoreduction operations had decreases in serum CA 125 levels only if there was a response to further therapy. The rate of fall of the CA 125 levels correlated with clinical outcome. All 13 patients with serum CA 125 above 35 U/mL after three months of treatment invariably had persistent tumors after subsequent chemotherapy, whereas in patients showing reduction of the CA 125 to levels below 35 U/mL, there were no surgically detectable tumors. Measurement of CA 125 during treatment might permit an early change to alternative and optimal forms of therapeutic management. The CA 125 level three months after treatment appears to be a critical predictor of response to therapy.(Obstet Gynecol69: 223, 1987)